Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous cultured chondrocyte implant - Vericel

Drug Profile

Autologous cultured chondrocyte implant - Vericel

Alternative Names: Autologous cultured chondrocytes; Carticel; Carticel II; Cartilage replacement - Genzyme

Latest Information Update: 25 May 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Vericel Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries

Most Recent Events

  • 10 May 2017 Autologous cultured chondrocyte implant - Vericel licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other countries in South-East Asia
  • 24 Aug 2015 Vericel has patent protection for autologous cultured chondrocyte implant in USA and European Union (Vericel 10-K, August 2015)
  • 24 Nov 2014 Aastrom Biosciences is now called Vericel Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top